NCM·Healthcare·$373M·#314 / 520 in Healthcare
IRD Opus Genetics, Inc.
37HIGH RISK
CATEGORY BREAKDOWN
GROWTH47
QUALITY0
STABILITY67
VALUATION4
GOVERNANCE50
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+29.1%
47
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
15 months
54
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
7.4%
94
< 25% strong
Price / Sales
Market cap relative to trailing revenue
26.3x
4
< 3x strong
Rule of 40
Growth rate plus operating margin
-243
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
15.2%
75
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+57.0%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE IRD WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when IRD's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.